Repaglinide, (-)- | CAS# 147852-26-4 | Biochemical

MedKoo Cat#: 573957 | Name: Repaglinide, (-)-

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Repaglinide, (-)-, is a Repaglinide impurity where only the R-enantiomer showed weak hypoglycemic activity.

Chemical Structure

Repaglinide, (-)-

CAS#147852-26-4

Theoretical Analysis

MedKoo Cat#: 573957

Name: Repaglinide, (-)-

CAS#: 147852-26-4

Chemical Formula: C27H36N2O4

Exact Mass: 452.2675

Molecular Weight: 452.59

Elemental Analysis: C, 71.65; H, 8.02; N, 6.19; O, 14.14

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

135062-02-1

Synonym

AG-EE 624ZW; Repaglinide specified impurity E; Repaglinide, (-)-

IUPAC/Chemical Name

2-Ethoxy-4-(2-(((1R)-3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid

InChi Key

FAEKWTJYAYMJKF-HSZRJFAPSA-N

InChi Code

1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m1/s1

SMILES Code

CCOc1cc(ccc1C(=O)O)CC(=O)N[C@H](CC(C)C)c2ccccc2N3CCCCC3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 452.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Safavi F, Andrade-Cetto A, Escandón-Rivera SM, Espinoza-Hernández FA. Assessing the potential fasting and postprandial mechanisms involved in the acute hypoglycemic and anti-hyperglycemic effects of four selected plants from Iran used in traditional Persian medicine. J Ethnopharmacol. 2025 Jan 10;336:118742. doi: 10.1016/j.jep.2024.118742. Epub 2024 Aug 27. PMID: 39197806. 2: Reddy GN, Jogvanshi A, Reddy DS, Chenkual L, Sonti R. DoE-assisted HPLC method development and validation of enzalutamide and repaglinide in rat plasma. Bioanalysis. 2024 Aug 8:1-15. doi: 10.1080/17576180.2024.2383070. Epub ahead of print. PMID: 39115061. 3: He Z, Dydio P. Photoinduced Cu(II)-Mediated Decarboxylative Thianthrenation of Aryl and Heteroaryl Carboxylic Acids. Angew Chem Int Ed Engl. 2024 Jul 16:e202410616. doi: 10.1002/anie.202410616. Epub ahead of print. PMID: 39012681. 4: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Repaglinide. 2024 Jul 15. PMID: 30000151. 5: Ghadhban HY, Ahmed KK. Nanosuspension-Based Repaglinide Fast-Dissolving Buccal Film for Dissolution Enhancement. AAPS PharmSciTech. 2024 Jul 12;25(6):161. doi: 10.1208/s12249-024-02868-w. PMID: 38992175. 6: Nag S, Stany B, Mishra S, Kumar S, Mohanto S, Ahmed MG, Mathew B, Subramaniyan V. Multireceptor Analysis for Evaluating the Antidiabetic Efficacy of Karanjin: A Computational Approach. Endocrinol Diabetes Metab. 2024 Jul;7(4):e509. doi: 10.1002/edm2.509. PMID: 38982323; PMCID: PMC11233261. 7: Demirturk E, Ugur Kaplan AB, Cetin M, Dönmez Kutlu M, Köse S, Akıllıoğlu K. Preparation of nanoparticle and nanoemulsion formulations containing repaglinide and determination of pharmacokinetic parameters in rats. Eur J Pharm Sci. 2024 Sep 1;200:106844. doi: 10.1016/j.ejps.2024.106844. Epub 2024 Jul 6. PMID: 38977205. 8: Hartauer M, Murphy WA, Brouwer KLR, Southall R, Neuhoff S. Hepatic OATP1B zonal distribution: Implications for rifampicin-mediated drug-drug interactions explored within a PBPK framework. CPT Pharmacometrics Syst Pharmacol. 2024 Jun 19. doi: 10.1002/psp4.13188. Epub ahead of print. PMID: 38898552. 9: Lever JEP, Turner KB, Fernandez CM, Leung HM, Hussain SS, Shei RJ, Lin VY, Birket SE, Chu KK, Tearney GJ, Rowe SM, Solomon GM. Metachrony drives effective mucociliary transport via a calcium-dependent mechanism. Am J Physiol Lung Cell Mol Physiol. 2024 Sep 1;327(3):L282-L292. doi: 10.1152/ajplung.00392.2023. Epub 2024 Jun 11. PMID: 38860289. 10: Hanukoglu A, Banne E, Lev D, Wainstein J. Autosomal Dominant, Long-Standing Dysglycemia in 2 Families with Unique Phenotypic Features. Clin Med Insights Endocrinol Diabetes. 2024 Jun 6;17:11795514241259740. doi: 10.1177/11795514241259740. PMID: 38854748; PMCID: PMC11159530. 11: Ijaz K, Zakiullah -, Shah H, Ali S, Raziq M, Bahadar H. Association of GRK5 variant rs10886471 with the therapeutic effect of repaglinide in patients of type 2 diabetes mellitus in Peshawar, Pakistan. Pak J Pharm Sci. 2024 Mar;37(2(Special)):417-421. PMID: 38822544. 12: de Vries M, Bonsmann S, Pausch J, Sumner M, Birkmann A, Zimmermann H, Kropeit D. Evaluation of the Clinical Drug-Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach. Clin Pharmacol Drug Dev. 2024 Jul;13(7):755-769. doi: 10.1002/cpdd.1408. Epub 2024 May 16. PMID: 38752475. 13: Tang Y, Yan M, Fang Z, Jin S, Xu T. Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice. BMJ Open Diabetes Res Care. 2024 May 6;12(3):e003837. doi: 10.1136/bmjdrc-2023-003837. PMID: 38719505; PMCID: PMC11085777. 14: Camara MD, Zhou Y, De Sousa TN, Gil JP, Djimde AA, Lauschke VM. Meta- analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences. Hum Genomics. 2024 Apr 22;18(1):40. doi: 10.1186/s40246-024-00610-y. PMID: 38650020; PMCID: PMC11034136. 15: Yan Z, Ma L, Hwang N, Huang J, Kenny JR, Hop CECA. Using the Dynamic Well- Stirred Model to Extrapolate Hepatic Clearance of Organic Anion-Transporting Polypeptide Transporter Substrates without Assuming Albumin-Mediated Hepatic Drug Uptake. Drug Metab Dispos. 2024 May 16;52(6):548-554. doi: 10.1124/dmd.124.001645. PMID: 38604729. 16: Dimnjaković J, Buble T, Ivanko P, Pristaš I, Brborović O, Brborović H. Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy. Sci Rep. 2024 Mar 27;14(1):7227. doi: 10.1038/s41598-024-57871-9. PMID: 38538694; PMCID: PMC10973387. 17: Dimnjaković J, Buble T, Ivanko P, Poljičanin T, Karanović Štambuk S, Brborović H, Brborović O. Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis. PLoS One. 2024 Mar 27;19(3):e0301056. doi: 10.1371/journal.pone.0301056. PMID: 38536830; PMCID: PMC10971752. 18: Cuan K, Bass IR. A Woman With HNF1A-Associated Monogenic Diabetes Treated Successfully With Repaglinide Monotherapy. AACE Clin Case Rep. 2023 Dec 16;10(2):49-51. doi: 10.1016/j.aace.2023.12.003. PMID: 38523849; PMCID: PMC10958634. 19: Bulchandani S, Kundra P. A Case of Maturity-Onset Diabetes of the Young With Complex Mutations. JCEM Case Rep. 2024 Mar 16;2(3):luae031. doi: 10.1210/jcemcr/luae031. PMID: 38495396; PMCID: PMC10943505. 20: Kahma H, Paludetto MN, Neuvonen M, Kurkela M, Filppula AM, Niemi M, Backman JT. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors. Eur J Pharm Sci. 2024 Jul 1;198:106735. doi: 10.1016/j.ejps.2024.106735. Epub 2024 Feb 27. PMID: 38423227.